TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06464315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Mapping/Imaging
Description: Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
Study: NCT05309083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Walking Therapy (MBWT)
Description: MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
Study: NCT05009992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib
Description: Given PO
Study: NCT04937699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-DAPT of Ticagrelor plus aspirin
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential monotherapy of Ticagrelor and clopidogrel
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
Study: NCT04894916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care Mobile (MDC-m)
Description: My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
Study: NCT05140382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be given intravenously
Study: NCT04607759

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutraceutical
Description: Subjects will consume two capsules for eight weeks
Study: NCT04906590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] PI-2620
Description: Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
Study: NCT05170360

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:
Description: 1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR
Study: NCT04607759

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutraceutical
Description: Subjects will consume two capsules for eight weeks
Study: NCT05714930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treat-to-target as a new treatment concept
Description: After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
Study: NCT06788730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model Based Healthy Internet Use Programme Intervention Supported by Mindfulness Exercise Applied to Adolescents
Description: Transtheoretical Model Based Healthy Internet Use Programme Supported by Mindfulness Exercise will be carried out as one session per week for 8 weeks. The training programme will be carried out by dividing the students into 2 groups (the first group is 18 and the second group is 19 people). The training programme will be applied to the groups two days in the same week at the times determined by the guidance teacher. Interventions will be applied to the intervention group with trainings, homework applications and interventions to increase healthy internet use.
Study: NCT05690386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Once-weekly subcutaneous injection of Lonapegsomatropin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Once-weekly subcutaneous injection of Lonapegsomatropin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Once-weekly subcutaneous injection of Lonapegsomatropin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Once-daily subcutaneous injection of Somatropin
Study: NCT05921643

Intervention type: DEVICE
Intervention: verre bioactif 45S5 GlassBONE
Description: All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.

Intervention type: DEVICE
Intervention: verre bioactif S53P4 Bonalive
Description: All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
Study: NCT05196399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan (Formulation A)
Description: A single oral dose of 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan (Formulation B)
Description: A single oral dose of 25 mg.
Study: NCT04489160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Inhibitor, Human
Description: 6000 IU C1-INH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT06126380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
Study: NCT05073068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timing of exercise
Description: An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timing of exercise
Description: An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
Study: NCT05742945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate lymphatic reconstruction
Description: Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
Study: NCT05327686

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: 42 Gy in 3 fractions
Study: NCT04367506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BecomeAnEX
Description: This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
Study: NCT05076591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2902
Description: a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
Study: NCT06097013

Intervention type: OTHER
Intervention: Routine clinical rehabilitation
Description: Routine clinical rehabilitation

Intervention type: OTHER
Intervention: Routine clinical rehabilitation
Description: Routine clinical rehabilitation
Study: NCT06788652

Intervention type: BIOLOGICAL
Intervention: Lisocabtagene maraleucel
Description: According to US Prescribing Information
Study: NCT06789107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab 9ug
Description: Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Study: NCT06790121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunsekimig
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunsekimig
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunsekimig
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
Study: NCT06789003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted exercises
Description: Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions.~For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook.~Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department.~Each session will last 45 minutes with a medium intensity according to the Borg scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life questionnaire
Description: QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life questionnaire
Description: QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire of Fatigue
Description: Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire of Fatigue
Description: Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity questionnaire
Description: Questionnaire (IPAQ) at baseline and after transplantation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity questionnaire
Description: Questionnaire (IPAQ) at baseline and after transplantation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical condition
Description: Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical condition
Description: Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation
Study: NCT06788431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-001
Description: Subjects receive IMC-001 administered by injection once a week for 9-12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: The control group subjects receive only optimal medical treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: The experimental group subjects also receive optimal medical treatment
Study: NCT06788873

Intervention type: OTHER
Intervention: Data comparison
Description: For each participant, information will be collected on:~* Gestational age at the time the cerclage was performed~* Parity~* Age~* BMI~* Ethnicity~* Number of preterm deliveries~* Gestational age of previous preterm deliveries~* Previous uterine and/or cervix surgery (previous cerclage, conization, metroplasty, or other)~* Type of cerclage performed~* Operative times~* Days of hospitalization~* Surgical complications~* Gestational age at the time of delivery~* Mode of delivery (spontaneous, operative or cesarean)~* Infant's weight at birth~* Apgar at 1' and 5' minute~* Ph newborn~* Possible admission to neonatal intensive care unit.

Intervention type: OTHER
Intervention: Data comparison
Description: For each participant, information will be collected on:~* Gestational age at the time the cerclage was performed~* Parity~* Age~* BMI~* Ethnicity~* Number of preterm deliveries~* Gestational age of previous preterm deliveries~* Previous uterine and/or cervix surgery (previous cerclage, conization, metroplasty, or other)~* Type of cerclage performed~* Operative times~* Days of hospitalization~* Surgical complications~* Gestational age at the time of delivery~* Mode of delivery (spontaneous, operative or cesarean)~* Infant's weight at birth~* Apgar at 1' and 5' minute~* Ph newborn~* Possible admission to neonatal intensive care unit.
Study: NCT06789874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Saline
Description: Intralesional Saline injected in scars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 35% trichloracetic acid peel
Description: 35%Trichloracetic acid peel was applied to scars monthly for 3 months
Study: NCT06788314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Each participant will receive a dose of enalapril 5 mg once daily. If the participant doesn't have effect of the intervention after 3 months, the dose of enalapril will be increased to 10 mg daily, if the tolerance of enalapril is good. Lack of effect will be defined as unchanged or increased NRS score.~Treatment duration will be 12 months.
Study: NCT06788795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device with Phone App
Description: This is the intervention where the patients will be given both the wearable dehydration device as well as the phone app

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device without Phone App
Description: This is the intervention where the patients will receive the device alone
Study: NCT06788392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminiscence therapy
Description: Reminiscence Therapy is a supportive care model that has been used in recent years and increases life comfort.
Study: NCT06789120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization
Description: In the study, the Graston device will be applied to the plantar flexor muscles of the patients. The medial and lateral gastarosoleus muscles and tendon will be applied deeply for 3 minutes, and the soleus muscle will be applied deeply for 90 seconds.
Study: NCT06789731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a loving kindness meditation adapted to apply to college communities and designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: In the psychoeducation arm, participants will receive information related to creating connections with campus community and managing anxiety and/or depression through a presentation. They will also receive information on resources for connecting with their community and treating anxiety and/or depression.
Study: NCT06788925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patients support with survival coverage
Description: Following calls to emergency medical services, handled by the ground SMUR/SAMU or the air SMUR (HéliSMUR), the operator collects essential information on the nature of the incident and the apparent condition of the injured. A medical team is thus mobilized on site. It takes over from the rescue team (e.g. the SDIS fi refi ghters) who are generally the fi rst to arrive on the scene.~Eligible patients will be randomly assigned consecutively to one of two groups: control (use of the survival blanket) and experimental (use of the Therm'Up breastplate).~Any traumatized person at risk of hypothermia or in hypothermia in a pre-hospital environment, having given verbal consent to participate in the study and meeting the inclusion criteria
Study: NCT05957874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined package program
Description: Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles.
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy